![Felicia Pagliuca](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Felicia Pagliuca
Oprichter bij Semma Therapeutics, Inc.
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Jeff Imbaro | M | - |
Semma Therapeutics, Inc.
![]() Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | 9 jaar |
Douglas A. Melton | M | 70 |
Semma Therapeutics, Inc.
![]() Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | 9 jaar |
Moses Goddard | M | - |
Semma Therapeutics, Inc.
![]() Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | - |
Stephen Knight | M | 63 |
Semma Therapeutics, Inc.
![]() Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | - |
Mitchell Finer | M | 65 |
Semma Therapeutics, Inc.
![]() Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | 9 jaar |
Auerbach Daniel | M | 66 |
Semma Therapeutics, Inc.
![]() Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | - |
William A. Sahlman | M | - |
Semma Therapeutics, Inc.
![]() Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Robert A. Millman | M | - |
Semma Therapeutics, Inc.
![]() Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | - |
Walter Blättler | M | 75 |
Semma Therapeutics, Inc.
![]() Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | - |
Mary Fenton | F | 60 |
Semma Therapeutics, Inc.
![]() Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | - |
Bastiano Sanna | M | 49 |
Semma Therapeutics, Inc.
![]() Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | 2 jaar |
Mark Fishman | M | 73 |
Semma Therapeutics, Inc.
![]() Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | 3 jaar |
David N. Cordo | M | - |
Semma Therapeutics, Inc.
![]() Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | - |
Elizabeth Stoner | M | 73 |
Semma Therapeutics, Inc.
![]() Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | 1 jaar |
David Lebwohl | M | 69 |
Semma Therapeutics, Inc.
![]() Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | - |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 15 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Felicia Pagliuca
- Persoonlijk netwerk